Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Naloxegol Oxalate
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : Grunenthal
Deal Size : $250.0 million
Deal Type : Acquisition
Grünenthal Continues US Growth Push with $250M Acquisition of Valinor Pharma
Details : Through the acquisition, Grunenthal will leverage the Valinor pipeline, which also includes Movantik (naloxegol), indicated for the treatment of OIC in adult patients with chronic non-cancer pain.
Brand Name : Movantik
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 22, 2024
Lead Product(s) : Naloxegol Oxalate
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : Grunenthal
Deal Size : $250.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?